ArticleACS omega2021
Machine Learning-Driven and Smartphone-Based Fluorescence Detection for CRISPR Diagnostic of SARS-CoV-2.
Article in ACS omega, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Evaluation of CRISPR-Based Assays for Rapid Detection of SARS-CoV-2: A Systematic Review and Meta-Analysis.Yonsei medical journal · 2022Pooled it
- Miniaturized CRISPR: Ultra Compact Systems for In Vivo Delivery and Portable Diagnostics.Annals of biomedical engineering · 2026Review
- A Dual-Port, Smartphone-Linked, Pocket-Size Fluorimeter for Rapid Molecular Diagnostic Assays at Point of Care.IEEE sensors journal · 2026Article
- Machine Learning for CRISPR-Based Diagnostics.International journal of molecular sciences · 2026Review
- Deep Learning-Assisted Digital Microfluidic Platform for Automated CRISPR/Cas12 Detection ofACS measurement science au · 2026Article
- Integrated Optothermal Paperfluidic Platform for Single-Step, Model-Driven CRISPR-Cas12a Diagnostics ofACS omega · 2026Article
- Overview in Machine-Learning-Assisted Sensing Techniques for Monitoring COVID-19.Micromachines · 2026Review
- An ERA-CRISPR/Cas12a Method for Highly Sensitive Detection of Human Adenovirus Type 55.Diagnostics (Basel, Switzerland) · 2025Article
- CRISPR-Cas-Based Diagnostics in Biomedicine: Principles, Applications, and Future Trajectories.Biosensors · 2025Review
- Integrating Genomic Data with the Development of CRISPR-Based Point-of-Care-Testing for Bacterial Infections.Current clinical microbiology reports · 2024Review
- Article
- Ultra-sensitive and specific detection of pathogenic nucleic acids using composite-excited hyperfine plasma spectroscopy combs sensitized by Au nanoarrays functionalized with 2D TaBiosensors & bioelectronics · 2023Article
- Review
- A Multiplexed Cas13-Based Assay with Point-of-Care Attributes for Simultaneous COVID-19 Diagnosis and Variant Surveillance.The CRISPR journal · 2023Article
- Towards Point of Care CRISPR-Based Diagnostics: From Method to Device.Journal of functional biomaterials · 2023Review
- Achieving broad availability of SARS-CoV-2 detections via smartphone-based analysis.Trends in analytical chemistry : TRAC · 2023Review
- Methylene Blue functionalized carbon nanodots combined with different shape gold nanostructures for sensitive and selective SARS-CoV-2 sensing.Sensors and actuators. B, Chemical · 2022Article
- Point-of-care CRISPR/Cas biosensing technology: A promising tool for preventing the possible COVID-19 resurgence caused by contaminated cold-chain food and packaging.Food frontiers · 2022Article
- COVID-19 active case findings based on self-collected saliva samples with CRISPR-Cas12a detection.Experimental biology and medicine (Maywood, N.J.) · 2022Article
- Highly Specific and Rapid Detection of Hepatitis C Virus Using RT-LAMP-Coupled CRISPR-Cas12 Assay.Diagnostics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rapid, accurate, and low-cost detection of SARS-CoV-2 is crucial to contain the transmission of COVID-19. Here, we present a cost-effective smartphone-based device coupled with machine learning-driven software that evaluates the fluorescence signals of the CRISPR diagnostic of SARS-CoV-2. The device consists of a three-dimensional (3D)-printed housing and low-cost optic components that allow excitation of fluorescent reporters and selective transmission of the fluorescence emission to a smartphone. Custom software equipped with a binary classification model has been developed to quantify the acquired fluorescence images and determine the presence of the virus. Our detection system has a limit of detection (LoD) of 6.25 RNA copies/μL on laboratory samples and produces a test accuracy of 95% and sensitivity of 97% on 96 nasopharyngeal swab samples with transmissible viral loads. Our quantitative fluorescence score shows a strong correlation with the quantitative reverse transcription polymerase chain reaction (RT-qPCR) Ct values, offering valuable information of the viral load and, therefore, presenting an important advantage over nonquantitative readouts.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.